Richard Finn, MD
Enriched profileProfessor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA (also Director, Signal Transduction and Therapeutics Research Program, and Director, Clinical Research Unit, UCLA Jonsson Comprehensive Cancer Center) · David Geffen School of Medicine at UCLA
Richard Finn is Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA (also Director, Signal Transduction and Therapeutics Research Program, and Director, Clinical Research Unit, UCLA Jonsson Comprehensive Cancer Center) at David Geffen School of Medicine at UCLA. OpenAlex indexes 775 publications with 83,997 citations (h-index 102); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Richard Finn as a Highly Cited Researcher (Clinical Medicine, 2021-2025).
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Richard Finn, MD, is Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA (also Director, Signal Transduction and Therapeutics Research Program, and Director, Clinical Research Unit, UCLA Jonsson Comprehensive Cancer Center). The public record shows 775 publications with 83,997 citations (h-index 102), centered on Hepatobiliary Cancer, Breast Cancer, Pancreatic Cancer. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 29 companies, 1 NIH-funded awards (2020–2026).
- Top research focus: Hepatobiliary Cancer
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 29 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 24 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- A Study of ZW251 in Participants With Advanced Solid Tumors
Sponsor: Zymeworks BC Inc.
- Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
Sponsor: Translational Research in Oncology
Industry payments
Updated 14 Oct 2026
29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GUERBET LLCProgram year20259 payments$47,462openpaymentsdata.cms.gov ↗
- F. Hoffmann-La Roche AGProgram year202510 payments$26,046openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year20258 payments$15,971openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
24%Kinase inhibitor17.5%Lenvima100%Part D<11 patientsPoly(ADP-Ribose) Polymerase Inhibitor6.4%Lynparza100%Part D<11 patientsCardiovascular
21.6%Loop diuretic15.2%Furosemide100%Part D≥14 patientsCalcium channel blocker6.4%Amlodipine Besylate100%Part D<11 patientsMetabolism & gastrointestinal
19.3%Serotonin-3 Receptor Antagonist9.9%Ondansetron Odt100%Part D<11 patientsOsmotic Laxative9.4%Lactulose100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2020–2026 per NIH RePORTER. The latest:
- Signal Transduction and Therapeutics (STT)
University of California Los Angeles
FY2026$83,093P30CA016042 - Signal Transduction and Therapeutics (STT)
University of California Los Angeles
FY2025$83,092P30CA016042
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/richard-finn-md-85db83dc
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/richard-finn-97531344
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
profiles.ucla.edu/richard.finn
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucla.edu ↗ - ResearchGate
researchgate.net/scientific-contributions/Richard-S-Finn-39781407
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
zailaboratory.com/leadership/richard-s-finn-m-d
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →zailaboratory.com ↗ - Spotify
backtable.com/shows/vi/contributors/dr-richard-finn
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →backtable.com ↗ - X / Twitter
x.com/NiuSanford/status/1756400266713379032
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - LinkedIn
LinkedIn profile identifying as Richard Finn, UCLA (auth-walled; not independently opened)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Editorial & leadership roles
journal and society appointments- Past President
International Liver Cancer Association (ILCA)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globaloncologyacademy.org ↗ - Editorial board member
Clinical Cancer Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - Associate editor
Breast Cancer Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctaforum.com ↗ - Editorial board
Journal of Hepatology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctaforum.com ↗ - Ad hoc reviewer for The New England Journal of Medicine
The Lancet, and Lancet Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctaforum.com ↗ - Member
ASCO, AACR, and ESMO
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine20212022202320242025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- 2026 Blue Faery Award for Excellence in Liver Cancer Research
Lifetime Impact Award, for leadership in HCC research including the phase 3 IMbrave150 study that led to FDA approval of atezolizumab plus bevacizumab
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →zailaboratory.com ↗
- Physician
Dumont-UCLA Liver Cancer Center, Department of Surgery, UCLA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Director
Clinical Research Unit, UCLA Jonsson Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ecancer.org ↗
- ASCO Post video (AACR Annual Meeting 2021) on treating HCC with atezolizumab
bevacizumab, and sorafenib
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - BackTable VI Podcast
interview on hepatocellular carcinoma, TACE, and immunotherapy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →backtable.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Edward Garon, MD
David Geffen School of Medicine at UCLA
Donald Tashkin, MD
David Geffen School of Medicine at UCLA
Aditya Bardia, MD
David Geffen School of Medicine at UCLA
Gottfried Konecny, MD
David Geffen School of Medicine at UCLA
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles